Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria

Rheumatic Disease Clinics of North America

Volumn 28, Issue 4, 2002, Pages 723-741

  Mastaglia, Frank L ^a,b,c   Phillips, Beverley A ^d  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CANCER RISK; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; MUSCLE DISEASE; MYOPATHY; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MORBIDITY; MYOSITIS; MYOSITIS, INCLUSION BODY; NEOPLASMS; POLYMYOSITIS; WORLD HEALTH;

EID: 0036866028     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(02)00021-2     Document Type: Review

References (60)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. 1. N Engl J Med 1975;292:344-7.
2. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
3. Verschuuren JJ, Badrising UA, Wintzen AR, et al. Inclusion body myositis. In: Emery AEH, editor. Diagnostic Criteria for Neuromuscular Disorders. London: Royal Society of Medicine; 1997. p. 81-4.
4. Patrick M, Buchbinder R, Jolley D, et al. Incidence of inflammatory myopathies in Victoria, Australia and evidence of spatial clustering. J Rheumatol 1999;26:1094-100. 1997;26:104-6.
5. Patrick M, Buchbinder R, Jolley D, et al. Incidence of inflammatory myopathies in Victoria, Australia and evidence of spatial clustering. J Rheumatol 1999;26:1094-100. 1997;26:104-6.
6. Oddis CV, Conte CG, Steen VD, et al. Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990;17:1329-34.
7. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970;48:715-23.
8. Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis-dermatomyositis in Israel, 1960-76. Isr J Med Sci 1980;16:197-200.
9. Symmons DPM, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: Results from a nation-wide study. Br J Rheumatol 1995;34:732-6.
10. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-2.
11. Felice KJ, North WA. Inclusion body myositis in Connecticut: Observations in 35 patients during an 8-year period. Medicine 2001;80:320-7.
12. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 2000;55:1385-7.
13. Koh ET, Seow A, Ong B, et al. Adult onset polymyositis/dermatomyositis: Clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 1993;52:857-61.
14. Araki S, Uchino M, Yoshida O. Epidemiologic study of multiple sclerosis, myasthenia gravis, and polymyositis in the city of Kumamoto, Japan. Clin Neurol 1983;23:838-41.
15. Iannou Y, Sultan S, Isenberg DA. Myositis overlap syndromes. Curr Opin Rheumatol 1999;11:468-74.
16. Amato AA, Barohn RJ. Idiopathic inflammatory myopathies. Neurologic Clinics 1997;15:615-48.
17. Medsger KA. Systemic sclerosis (scleroderma), eosinophilic fasciitis and calcinosis. In: McCarty DJ, editor. Arthritis and allied conditions. 10th edition. Philadelphia: Lea & Febiger; 1985. p. 994-1036.
18. Foote RA, Kimbrough SM, Stevens JC. Lupus myositis. Muscle Nerve 1982;5:65-8.
19. Follansbee WP, Zerve TR, Medsger TA. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association. Am Heart J 1993;125(1):194-203.
20. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatol 1999;38:397-400.
21. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
22. Clements PJ, Furst DE, Campion DS, et al. Muscle disease in progressive systemic sclerosis: Diagnostic and therapeutic considerations. Arth Rheum 1978;21(1):62-71.
23. Reference deleted in proof.
24. Airio A, Pukkala A, Isomäki H. Elevated cancer incidence in patients with dermatomyositis: A population based study. J Rheumatol 1995;22:1300-3.
25. Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. Ann Intern Med 2001;134:1087-95.
26. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study. Lancet 2001;357:96-100.
27. Chow W, Gridley G, Mellemkjær L, et al. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes Control 1995;6:9-13.
28. Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis: A population-based study. N Engl J Med 1992;326:363-7.
29. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9.
30. Fung WKJ, Chang HLH, Lam WMW. Amyopathic dermatomyositis in Hong Kong - Association with nasopharyngeal carcinoma. Int J Dermatol 1998;37:659-63.
31. Engel AG, Hohlfeld R, Banker BQ. Inflammatory myopathies: The polymyositis and dermatomyositis syndromes. In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd Edition. New York: McGraw-Hill; 1994. p. 1335-83.
32. Bernard P, Bonnetblanc J. Dermatomyositis and malignancy. J Invest Dermatol 1993;100:128S-32S.
33. Reference deleted in proof.
34. Whitmore SE, Watson R, Rosenshein NB. Dermatomyositis sine myositis: Association with malignancy. J Rheumatol 1996;23:101-5.
35. Dalakas MC. Retrovirus and inflammatory myopathies in humans and primates. Bailliere's Clinical Neurology 1993;2:659-91.
36. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
37. Oldfors A, Lindberg C. Inclusion body myositis. Curr Opin Neurol 1999;12:527-33.
38. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: Clinical and pathological boundaries. Ann Neurol 1996;40:581-6.
39. Phillips BA, Cala LA, Thickbroom GW, et al. Patterns of muscle involvement in sporadic inclusion body myositis. A clinical and MRI study. Muscle Nerve 2001;24:1526-34.
40. Ojeda VJ, Mastaglia FL. Miscellaneous conditions. In: Inflammatory Diseases of Muscle. Mastaglia FL, editor. Oxford (UK): Blackwell Scientific Publications; 1988. p. 185-195.
41. Slavin ML, Glaser JS. Idiopathic orbital myositis. Report of six cases. Arch Ophthalmol 1982;100:1261-5.
42. Cumming WJK, Weiser R, Teoh R, et al. Localized nodular myositis: A clinical and pathological variant of polymyositis. Q J Med 1977;46:531-46.
43. Heffner RR, Armbrustmacher VW, Earlie KM. Focal myositis. Cancer 1977;40:301-6.
44. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic myofascitis: An emerging entity. Lancet 1998;352:347-52.
45. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipe-stem capillaries microvascular deposition of the complement membrane attack complex (MAC) and minimal cellular infiltration. Neurology 1991;41:936-9.
46. Targoff IN, Miller FW, Medsger TA, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rhematol 1997;9:527-35.
47. Tanimoto K, Nakano K, Kano S, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995;22:668-74.
48. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2000;12:482-91.
49. Garlepp MJ, Laing B, Zilko PJ, et al. HLA associations with inclusion body myositis. Clin Exp Immunol 1994;98:40-5.
50. Leff FL, Burgess SH, Miller FW, et al. Distinct patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-I and anti-signal recognition particle autoantibodies. Arthritis Rheum 1991;34:1391-6.
51. Manta P, Kalfakis N, Vassilopoulos D. Evidence for seasonal variation in polymyositis. Neuroepidemiology 1989;8:262-5.
52. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children. J Rheumatol 1998;25:1198-204.
53. Phillips BA, Zilko PJ, Garlepp MJ, et al. Seasonal occurrence of relapses in inflammatory myopathies: A preliminary study. J Neurol 2002;249:441-4.
54. Weitoft T. Occurrence of polymyositis in the county of Gävleborg, Sweden. Scand J Rheumatol 1997;26:104-6.
55. Kaipiainen-Seppänen O, Aho K. Incidence of rare systemic rheumatic and connective tissue diseases in Finland. J Intern Med 1996;240:81-4.
56. Darin M, Tulinius M. Neuromuscular disorders in childhood: A descriptive epidemiological study from western Sweden. Neuromusc Disord 2000;10:1-9.
57. Hanissian AS, Masi AT, Pitner SE, et al. Polymyositis and dermatomyositis in children: An epidemiologic and clinical comparative analysis. J Rheumatol 1982;9:390-4.
58. Lindberg C, Persson LI, Bjorkander J, et al. Inclusion body myositis: Clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-31.
59. Maoz CR, Langevitz P, Livneh A, et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: An 11-year analysis. Semin Arthritis Rheum 1998;27(5):319-24.
60. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy: A multicentre cooperative study. Dermatologica 1990;180:212-6.